What the business is, and whether it's a good one at a fair price.
Operates a diagnostic testing network with central laboratories and patient collection centres across India. In FY26, it added 14 new labs and over 1,100 collection centres, taking the network wider; revenue for the year was Rs. 2,763 crore, up 12.2% year-on-year. Around 75% of revenue comes from B2C patients and the balance from B2B referrals (doctors, hospitals and institutions). The Swasthfit preventive-health package brand contributed 27% of FY26 revenue, while Sovaaka — an AI-powered premium wellness screening brand — was launched with one centre in January 2026. Tier 3+ cities now account for 39% of revenue, and the company is expanding internationally through a Dubai subsidiary and an 80% stake in Ghana's Sunshine Healthcare. The largest cost line is materials (reagents and consumables) at 19.3% of revenue, followed by employee costs at 18.2% and other operating expenses at 34.1%.
Measured from the filed financials, judged against its Healthcare Service Provider peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from DR. LAL PATH LABS LTD.'s filed financials and exchange disclosures
DR. LAL PATH LABS LTD. is a Healthcare Services company listed on NSE and BSE, trading under the symbol LALPATHLAB.
Yes. Over the trailing twelve months DR. LAL PATH LABS LTD. reported a net profit of ₹546 Cr on revenue of ₹2,891 Cr.
Yes. The dividend yield is 0.70% at the current price. It paid out 44% of its profit as dividend in FY26.
Effectively yes. It holds ₹243 Cr more cash than debt. Debt stands at 0.00× equity.
On trailing P/E, DR. LAL PATH LABS LTD. ranks 20 of 29 in Healthcare Service Provider — cheaper than 32% of them, against an industry median of 23.2×. This is a position, not a valuation judgement.
On a typical session DR. LAL PATH LABS LTD. moves 1.14% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by DR. LAL PATH LABS LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
